The commonalities between cardiovascular, renal and metabolic (CaReMe) diseases are increasingly recognized, both in disease mechanisms and clinical syndromes. The overlap between CaReMe diseases results in high mortality and morbidity burden as well as challenges to a health system that largely addresses each comorbidity in isolation. Large-scale electronic health records and advances in data analytics offer opportunities to studying these diseases together at population level. The overall aim, in collaboration with Astra-Zeneca, is to support the identification of potential gaps in diagnostic and treatment pathways in at-risk patient groups with diabetes mellitus, heart failure and chronic kidney disease.